HIRA: molecules with a published decision record
111 molecules on this site carry at least one HIRA decision. Each page compares that decision with every other agency that assessed the same molecule.
| Molecule | Decisions | Agencies | Class |
|---|---|---|---|
| pembrolizumab | 371 | 15 | Antineoplastics |
| nivolumab | 264 | 15 | Antineoplastics |
| atezolizumab | 120 | 14 | Antineoplastics |
| dupilumab | 116 | 15 | Other dermatologicals |
| daratumumab | 115 | 15 | Antineoplastics |
| durvalumab | 108 | 15 | Antineoplastics |
| upadacitinib | 93 | 16 | Immunosuppressants |
| blinatumomab | 64 | 14 | Antineoplastics |
| trastuzumab deruxtecan | 64 | 14 | Antineoplastics |
| venetoclax | 61 | 14 | Antineoplastics |
| mepolizumab | 59 | 15 | Obstructive airway diseases |
| ipilimumab | 58 | 14 | Antineoplastics |
| zanubrutinib | 58 | 16 | Antineoplastics |
| cabozantinib | 56 | 15 | Antineoplastics |
| risankizumab | 56 | 14 | Immunosuppressants |
| bimekizumab | 55 | 14 | Immunosuppressants |
| ravulizumab | 54 | 15 | Immunosuppressants |
| selpercatinib | 53 | 13 | Antineoplastics |
| semaglutide | 53 | 14 | Diabetes |
| nintedanib | 49 | 15 | Antineoplastics |
| tislelizumab | 48 | 12 | Antineoplastics |
| abemaciclib | 47 | 15 | Antineoplastics |
| amivantamab | 47 | 13 | Antineoplastics |
| omalizumab | 43 | 12 | Obstructive airway diseases |
| avelumab | 42 | 13 | Antineoplastics |
| niraparib | 42 | 15 | Antineoplastics |
| dostarlimab | 39 | 14 | Antineoplastics |
| darolutamide | 38 | 15 | Endocrine therapy |
| alirocumab | 37 | 13 | Lipid modifying agents |
| burosumab | 34 | 13 | Bone diseases |
| cetuximab | 34 | 9 | Antineoplastics |
| pegcetacoplan | 33 | 16 | Ophthalmologicals |
| benralizumab | 31 | 15 | Obstructive airway diseases |
| canakinumab | 31 | 10 | Immunosuppressants |
| sacituzumab govitecan | 31 | 15 | Antineoplastics |
| larotrectinib | 29 | 14 | Antineoplastics |
| apalutamide | 28 | 12 | Endocrine therapy |
| apremilast | 28 | 10 | Immunosuppressants |
| belimumab | 28 | 12 | Immunosuppressants |
| encorafenib | 28 | 12 | Antineoplastics |
| ocrelizumab | 28 | 12 | Immunosuppressants |
| tafamidis | 28 | 16 | Other nervous system |
| enfortumab vedotin | 27 | 13 | Antineoplastics |
| vutrisiran | 27 | 15 | Other nervous system |
| fenfluramine | 26 | 14 | Antiepileptics |
| filgotinib | 26 | 13 | Immunosuppressants |
| lorlatinib | 26 | 12 | Antineoplastics |
| azacitidine | 25 | 11 | Antineoplastics |
| brolucizumab | 24 | 11 | Ophthalmologicals |
| mirikizumab | 24 | 12 | Immunosuppressants |
| odevixibat | 24 | 13 | Bile and liver therapy |
| ozanimod | 24 | 12 | Immunosuppressants |
| paclitaxel | 24 | 6 | Antineoplastics |
| epcoritamab | 23 | 14 | Antineoplastics |
| lanadelumab | 23 | 15 | Other hematological agents |
| polatuzumab vedotin | 23 | 13 | Antineoplastics |
| asciminib | 22 | 15 | Antineoplastics |
| pitolisant | 22 | 11 | Other nervous system |
| abrocitinib | 21 | 13 | Other dermatologicals |
| finerenone | 21 | 11 | Renin-angiotensin system |
| galcanezumab | 21 | 13 | Analgesics |
| ivosidenib | 21 | 12 | Antineoplastics |
| fremanezumab | 20 | 13 | Analgesics |
| pirtobrutinib | 20 | 14 | Antineoplastics |
| romosozumab | 20 | 13 | Bone diseases |
| gilteritinib | 18 | 13 | Antineoplastics |
| nemolizumab | 18 | 11 | Other dermatologicals |
| selumetinib | 18 | 14 | Antineoplastics |
| mavacamten | 17 | 13 | Cardiac therapy |
| teclistamab | 17 | 12 | Antineoplastics |
| avacopan | 16 | 11 | Immunosuppressants |
| bosutinib | 16 | 10 | Antineoplastics |
| brivaracetam | 16 | 7 | Antiepileptics |
| eplerenone | 16 | 6 | Diuretics |
| pegvisomant | 16 | 8 | Pituitary and hypothalamic hormones |
| fedratinib | 15 | 12 | Antineoplastics |
| ipilimumab / nivolumab | 15 | 6 | Antineoplastics |
| lebrikizumab | 15 | 13 | Other dermatologicals |
| maribavir | 15 | 14 | Antivirals |
| mogamulizumab | 15 | 11 | Antineoplastics |
| nirmatrelvir / ritonavir | 15 | 11 | Antivirals |
| zolbetuximab | 15 | 12 | Antineoplastics |
| delgocitinib | 14 | 12 | Other dermatologicals |
| fruquintinib | 14 | 13 | Antineoplastics |
| ixazomib | 14 | 10 | Antineoplastics |
| osilodrostat | 14 | 11 | Systemic corticosteroids |
| pemigatinib | 14 | 12 | Antineoplastics |
| trabectedin | 14 | 6 | Antineoplastics |
| beclometasone / formoterol / glycopyrronium | 13 | 5 | Antidiarrheals / intestinal anti-inflammatories |
| daptomycin | 13 | 4 | Antibacterials |
| dimethyl | 13 | 8 | Immunosuppressants |
| marstacimab | 13 | 12 | Antihemorrhagics |
| pralsetinib | 13 | 12 | Antineoplastics |
| tralokinumab | 13 | 9 | Other dermatologicals |
| asfotase alfa | 12 | 10 | Other alimentary tract and metabolism |
| danicopan | 12 | 11 | Immunosuppressants |
| deucravacitinib | 12 | 10 | Immunosuppressants |
| donepezil | 12 | 5 | Psychoanaleptics |
| inotuzumab ozogamicin | 12 | 10 | Antineoplastics |
| zilucoplan | 12 | 11 | Immunosuppressants |